NasdaqGS:GILDBiotechs
Gilead Sciences (NasdaqGS:GILD) Showcases Promising Liver Disease Treatments At EASL Congress
Gilead Sciences (NasdaqGS:GILD) recently announced a presentation at the EASL Congress focusing on liver disease, with promising research in both hepatitis B and C. This comes alongside solid Q1 earnings results where a significant net income turnaround was noted. These developments, combined with a quarterly dividend declaration and ongoing share buybacks, potentially supported a 13% share price increase over the last quarter. Meanwhile, the general market showed strength with a 7% rise,...